These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27267320)

  • 21. Long noncoding RNA GHET1 promotes the development of bladder cancer.
    Li LJ; Zhu JL; Bao WS; Chen DK; Huang WW; Weng ZL
    Int J Clin Exp Pathol; 2014; 7(10):7196-205. PubMed ID: 25400817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
    Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.
    Zhao XL; Zhao ZH; Xu WC; Hou JQ; Du XY
    Int J Clin Exp Pathol; 2015; 8(2):1954-60. PubMed ID: 25973088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide screening and identification of long noncoding RNAs and their interaction with protein coding RNAs in bladder urothelial cell carcinoma.
    Wang L; Fu D; Qiu Y; Xing X; Xu F; Han C; Xu X; Wei Z; Zhang Z; Ge J; Cheng W; Xie HL
    Cancer Lett; 2014 Jul; 349(1):77-86. PubMed ID: 24705305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of differentially expressed profiles of lncRNAs and circRNAs with associated co-expression and ceRNA networks in bladder carcinoma.
    Huang M; Zhong Z; Lv M; Shu J; Tian Q; Chen J
    Oncotarget; 2016 Jul; 7(30):47186-47200. PubMed ID: 27363013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.
    Bartsch G; Mitra AP; Mitra SA; Almal AA; Steven KE; Skinner DG; Fry DW; Lenehan PF; Worzel WP; Cote RJ
    J Urol; 2016 Feb; 195(2):493-8. PubMed ID: 26459038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.
    Luo M; Li Z; Wang W; Zeng Y; Liu Z; Qiu J
    Cancer Lett; 2013 Jun; 333(2):213-21. PubMed ID: 23354591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).
    Zhou Q; Chen J; Feng J; Wang J
    Tumour Biol; 2016 Mar; 37(3):3105-13. PubMed ID: 26427660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
    Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
    Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of long non-coding RNA SBF2-AS1 promotes proliferation in non-small cell lung cancer.
    Lv J; Qiu M; Xia W; Liu C; Xu Y; Wang J; Leng X; Huang S; Zhu R; Zhao M; Ji F; Xu L; Xu K; Yin R
    J Exp Clin Cancer Res; 2016 May; 35():75. PubMed ID: 27154193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
    Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
    J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth.
    Zhang H; Jiang H; Wang W; Gong J; Zhang L; Chen Z; Ding Q
    Urol Oncol; 2012; 30(6):920-7. PubMed ID: 21478038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer.
    Qu S; Yang X; Song W; Sun W; Li X; Wang J; Zhong Y; Shang R; Ruan B; Zhang Z; Zhang X; Li H
    Tumour Biol; 2016 Mar; 37(3):3933-8. PubMed ID: 26482611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder.
    Pei L; Yan D; He Q; Kong J; Yang M; Ruan H; Lin Q; Huang L; Huang J; Lin T; Qin H
    Cell Oncol (Dordr); 2023 Oct; 46(5):1509-1527. PubMed ID: 37355516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer.
    Gao S; Wang P; Hua Y; Xi H; Meng Z; Liu T; Chen Z; Liu L
    Oncotarget; 2016 Jan; 7(2):1608-18. PubMed ID: 26636540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
    Huang S; Qing C; Huang Z; Zhu Y
    Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.